Current Report Filing (8-k)
June 19 2018 - 3:47PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): June 19, 2018
CELGENE
CORPORATION
(Exact name of registrant as specified
in its charter)
|
|
|
|
|
Delaware
|
|
001-34912
|
|
22-2711928
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
86 Morris Avenue, Summit,
New Jersey
|
|
07901
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number,
including area code: (908) 673-9000
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange
Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
On June 19, 2018, Celgene Corporation announced that Jonathan
Biller will succeed Gerald F. Masoudi as Executive Vice President and General Counsel effective July 3, 2018.
Mr. Masoudi is leaving Celgene to return to Washington, D.C. with his family and assume the role of Chief Legal Officer with a
private company outside of the biopharmaceutical industry.
Attached hereto and incorporated by reference as Exhibit 99.1
is the Press Release announcement.
|
ITEM 9.01
|
FINANCIAL STATEMENTS AND EXHIBITS
|
Exhibit 99.1 – Press Release dated June 19, 2018
SIGNATURES
Pursuant to the requirements of the Securities and Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
CELGENE CORPORATION
|
|
|
|
|
Date: June 19, 2018
|
By:
|
|
/s/ Peter N. Kellogg
|
|
|
|
Peter N. Kellogg
|
|
|
|
Executive Vice President and Chief Financial Officer
|
|
|
|
(Principal Financial and Accounting Officer)
|
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Apr 2023 to Apr 2024
Real-Time news about Celgene Corporation (NASDAQ): 0 recent articles
More Celgene Corp /de/ News Articles